Fulvestrant ups PFS in Advanced Breast Cancer

besa

http://www.medpagetoday.com/meetingcoverage/esmo/6...

"Women with advanced/metastatic, hormone receptor (HR)-positive breast cancer had a significantly lower risk of disease progression or death if they received fulvestrant (Faslodex) as initial hormonal therapy, according to a randomized trial reported here. First-line treatment with the selective estrogen receptor degrader (SERD) led to a median progression-free survival of 16.6 months versus 13.8 months with the aromatase inhibitor anastrozole (Arimidex). Subgroup analysis revealed a consistent advantage in favor of fulvestrant."

"Action Points:

Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

Women with advanced/metastatic, hormone receptor (HR)-positive breast cancer had a significantly lower risk of disease progression or death if they received fulvestrant (Faslodex) as initial hormonal therapy.

Note that rates of adverse events, serious adverse events, and adverse events leading to discontinuation were similar between those who received fulvestrant compared with those who received anastrozole."